The anti VEGF antibody, bevacizumab, has demonstrated a survival benefit across several malignancies and has also demonstrated early promising results in head and neck cancer, producing responses in both the primary and metastatic setting [5, 17–19]. Here, VEGFA is linked to head and neck cancer.